File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy

TitleAdvances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy
Authors
KeywordsCarcinoid
Pancreatic
Neuroendocrine
Sunitinib
Everolimus
Issue Date2012
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmcaca
Citation
Anti-Cancer Agents in Medicinal Chemistry, 2012, v. 13 n. 3, p. 382-388 How to Cite?
AbstractNeuroendocrine tumors (NETs) are heterogeneous in underlying tumor biology and clinical presentations. They are generally classified according to their degree of differentiation and sites of origin. Moreover, NETs are further characterized by their secreted bioactive neuroamine. The treatment paradigm used to be surgical intervention in early disease and mostly palliative nature in the metastatic setting. With an increase in the understanding of the molecular signaling pathways involved in tumor growth, there are various emerging treatment options for patients with advanced NETs. Somatostatin analogs have both anti-tumor effects as well as symptom palliation associated with the secreted neuropeptides. Peptide-radio-receptor treatment (PRRT) using radio-labeled peptides which binds to somatostatin receptor is a useful anti-tumor treatment but limited by general availability. Sunitinib, a multi-targeted tyrosine kinase inhibitor, has recently been shown to improve the survival of pancreatic NETs patients. Similarly, the use of an mTOR inhibitor - everolimus, either alone or in combination with somatostatin analogs have demonstrated encouraging efficacy in treating advanced NETs. The success of these two agents in pancreatic NETS supports the notion that targeting angiogenesis and/or PI3K/AKT/mTOR pathway is an important strategy for making therapeutic advances in this disease. There are now many ongoing trials in exploring the role of other novel agents in treating patients with pancreatic NETs or carcinoid. The major plaguing problem in this era is the differential response to biological agents amongst NETs of different anatomical origins. Pancreatic NETs are generally more responsive to both chemotherapy and targeted agents than NETs of other sites. Thus, the development of potential predictive and prognostic biomarkers to tailor various molecular therapies to different NETs populations is a major unmet need.
Persistent Identifierhttp://hdl.handle.net/10722/174124
ISSN
2015 Impact Factor: 2.722

 

DC FieldValueLanguage
dc.contributor.authorLeung, Ren_US
dc.contributor.authorLang, Ben_US
dc.contributor.authorWong, Hen_US
dc.contributor.authorChiu, Jen_US
dc.contributor.authorWan, KYen_US
dc.contributor.authorShek, Ten_US
dc.contributor.authorWoo, YCen_US
dc.contributor.authorLo, CYen_US
dc.contributor.authorYau, Ten_US
dc.date.accessioned2012-11-16T03:35:38Z-
dc.date.available2012-11-16T03:35:38Z-
dc.date.issued2012en_US
dc.identifier.citationAnti-Cancer Agents in Medicinal Chemistry, 2012, v. 13 n. 3, p. 382-388en_US
dc.identifier.issn1871-5206-
dc.identifier.urihttp://hdl.handle.net/10722/174124-
dc.description.abstractNeuroendocrine tumors (NETs) are heterogeneous in underlying tumor biology and clinical presentations. They are generally classified according to their degree of differentiation and sites of origin. Moreover, NETs are further characterized by their secreted bioactive neuroamine. The treatment paradigm used to be surgical intervention in early disease and mostly palliative nature in the metastatic setting. With an increase in the understanding of the molecular signaling pathways involved in tumor growth, there are various emerging treatment options for patients with advanced NETs. Somatostatin analogs have both anti-tumor effects as well as symptom palliation associated with the secreted neuropeptides. Peptide-radio-receptor treatment (PRRT) using radio-labeled peptides which binds to somatostatin receptor is a useful anti-tumor treatment but limited by general availability. Sunitinib, a multi-targeted tyrosine kinase inhibitor, has recently been shown to improve the survival of pancreatic NETs patients. Similarly, the use of an mTOR inhibitor - everolimus, either alone or in combination with somatostatin analogs have demonstrated encouraging efficacy in treating advanced NETs. The success of these two agents in pancreatic NETS supports the notion that targeting angiogenesis and/or PI3K/AKT/mTOR pathway is an important strategy for making therapeutic advances in this disease. There are now many ongoing trials in exploring the role of other novel agents in treating patients with pancreatic NETs or carcinoid. The major plaguing problem in this era is the differential response to biological agents amongst NETs of different anatomical origins. Pancreatic NETs are generally more responsive to both chemotherapy and targeted agents than NETs of other sites. Thus, the development of potential predictive and prognostic biomarkers to tailor various molecular therapies to different NETs populations is a major unmet need.-
dc.languageengen_US
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cmcaca-
dc.relation.ispartofAnti-Cancer Agents in Medicinal Chemistryen_US
dc.subjectCarcinoid-
dc.subjectPancreatic-
dc.subjectNeuroendocrine-
dc.subjectSunitinib-
dc.subjectEverolimus-
dc.titleAdvances in the systemic treatment of neuroendocrine tumors in the era of molecular therapyen_US
dc.typeArticleen_US
dc.identifier.emailLang, B: blang@hkucc.hku.hken_US
dc.identifier.emailShek, T: whshek@hkucc.hku.hken_US
dc.identifier.emailWoo, YC: wooyucho@hku.hken_US
dc.identifier.emailLo, CY: cylo@hkucc.hku.hken_US
dc.identifier.emailYau, T: tyaucc@hku.hken_US
dc.identifier.authorityYau, T=rp01466en_US
dc.identifier.doi10.2174/1871520611313030002-
dc.identifier.pmid23092266-
dc.identifier.scopuseid_2-s2.0-84876729549-
dc.identifier.hkuros216935en_US
dc.identifier.volume13-
dc.identifier.issue3-
dc.identifier.spage382-
dc.identifier.epage388-
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats